Systematic Review

Medical School, The University of Western Australia, Perth, Western Australia

*Author for correspondence: Tel.: +61 8 9224 0201; Fax: +61 8 9224 0279; Mobile: +61 412 299 025;

E-mail Address: stephan.schug@uwa.edu.au

Medical School, The University of Western Australia, Perth, Western Australia

Published Online:6 Aug 2018https://doi.org/10.2217/pmt-2018-0027

Abstract

Background: Tapentadol is a novel atypical opioid. Anecdotal evidence suggests that tapentadol has a lower toxicity than conventional opioids. Objectives: To evaluate all single-drug mortality due to tapentadol and assess serious adverse events caused by tapentadol. Methods: The Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) reporting guidelines, an evidence-based minimum set of items for reporting in systematic reviews, were followed in this systematic review. Results: 24 peer-reviewed papers were identified. They indicate that tapentadol toxicity can cause mortality and serious adverse effects. Conclusion(s): At least four confirmed fatalities, and serious adverse effects have been documented for individuals abusing or using tapentadol as prescribed. Serious adverse effects of tapentadol use may include respiratory depression, confusion, coma, hallucination/delusion, seizures, tachycardia, hypertension, agitation, tremor, miosis, hypotension, dyspnea, electrolyte abnormality, atrial fibrillation or severe upper abdominal pain. Tapentadol is unlikely to cause serotonin syndrome. The toxicity of tapentadol is significantly less than pure mu opioids, such as oxycodone.

Keywords:

References

1 Department of Health. Tapentadol, tablet, 50mg, 100mg, 150mg, 200mg and 250mg (as hydrochloride) (sustained release), Palexia SR^® – November 2013. The Pharmaceutical Benefits Scheme 2017 (23 August 2013). www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/tapentadol..
Google Scholar
2 US FDA Drug Approval Package Tapentadol Hydrochloride Tablets. Application No.: 022304, Approval Date: 12/24/2008. www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022304s000_TOC.cfm.
Google Scholar
3 Emc. Palexia SR prolonged release tablets (2018). www.medicines.org.uk/emc/product/5158/smpc.
Google Scholar
4 Ventura L, Carvalho F, Dinis-Oliveira RJ. Opioids in the frame of new psychoactive substances network: a complex pharmacological and toxicological issue. Curr. Mol. Pharmacol. 04, 04 (2017).
Google Scholar
5 Tzschentke TM, Christoph T, Schroder W et al. Tapentadol: With two mechanisms of action in one molecule effective against nociceptive and neuropathic pain: Preclinical overview. [German]. Schmerz 25(1), 19–25 (2011).
Medline CASGoogle Scholar
6 Knezevic NN, Tverdohleb T, Knezevic I, Candido KD. Unique pharmacology of tapentadol for treating acute and chronic pain. Expert Opin. Drug Metabol. Toxicol. 11(9), 1475–1492 (2015).
Medline CASGoogle Scholar
7 Schroder W, Vry JD, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur. J. Pain 14(8), 814–821 (2010).
MedlineGoogle Scholar
8 Hartrick CT, Rozek RJ. Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 25(5), 359–370 (2011).
Medline CASGoogle Scholar
9 Raffa RB, Buschmann H, Christoph T et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin. Pharmacother. 13(10), 1437–1449 (2012).
Medline CASGoogle Scholar
10 Tzschentke TM, Christoph T, Kogel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 28(4), 319–329 (2014).
Medline CASGoogle Scholar
11 Lange B, Von Zabern D, Elling C, Dubois C. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr. Med. Res. Opin. 33(8), 1413–1422 (2017).
Medline CASGoogle Scholar
12 Afilalo M, Etropolski MS, Kuperwasser B et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled Phase III study. Clin. Drug Investig. 30(8), 489–505 (2010).
Medline CASGoogle Scholar
13 Baron R, Eberhart L, Kern KU et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Practice 17(5), 678–700 (2017).
MedlineGoogle Scholar
14 Baron R, Likar R, Martin-Mola E et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone pr for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase 3b/4 study. Pain Pract. 16(5), 580–599 (2016).
MedlineGoogle Scholar
15 Barbosa J, Faria J, Queiros O, Moreira R, Carvalho F, Dinis-Oliveira RJ. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metab. Rev. 48(4), 577–592 (2016).
Medline CASGoogle Scholar
16 Afilalo M, Stegmann JU, Upmalis D. Tapentadol immediate release: a new treatment option for acute pain management. J. Pain Res. 3, 1–9 (2010).
Medline CASGoogle Scholar
17 Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Phys. 16(3), E237–e246 (2013).
MedlineGoogle Scholar
18 Daniels SE, Golf M. Clinical efficacy and safety of tapentadol immediate release in the postoperative setting. J. Am. Podiatr. Med. Assoc. 102(2), 139–148 (2012).
MedlineGoogle Scholar
19 Centres for Disease Control and Prevention. NCHS data on drug-poisoning deaths (2017). www.cdc.gov/nchs/data/factsheets/factsheet_drug_poisoning.pdf
Google Scholar
20 Fox L, Hoffman RS, Vlahov D, Manini AF. Clinical risk factors in Emergency Department (ED) patients with prescription opioid overdose. Clin. Toxicol. 53(4), 236 (2015).
Google Scholar
21 Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 6(7), e1000097 (2009).
MedlineGoogle Scholar
22 Baron R, Kern U, Muller M, Dubois C, Falke D, Steigerwald I. Effectiveness and tolerability of a moderate dose of tapentadol prolonged release for managing severe, chronic low back pain with a neuropathic component: an open-label continuation arm of a randomized Phase 3b study. Pain Pract. 15(5), 471–486 (2015).
MedlineGoogle Scholar
23 Banerjee M, Mondal S, Sarkar R, Mondal H, Bhattacharya K. Comparative study of efficacy and safety of tapentadol versus etoricoxib in mild to moderate grades of chronic osteorthritis of knee. Ind. J. Rheumatol. 11(1), 21–25 (2016).
Google Scholar
24 Buynak R, Rappaport SA, Rod K et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin. Therapeut. 37(11), 2420–2438 (2015).
Medline CASGoogle Scholar
25 Buynak R, Shapiro DY, Okamoto A et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin. Pharmaco. 11(11), 1787–1804 (2010).
Medline CASGoogle Scholar
26 Eichenbaum G, Gohler K, Etropolski M et al. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. J. Opioid Manag. 11(3), 211–227 (2015).
MedlineGoogle Scholar
27 Imanaka K, Tominaga Y, Etropolski M et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr. Med. Res. Opin. 29(10), 1399–1409 (2013).
Medline CASGoogle Scholar
28 Oh C, Rengelshausen J, Mangold B et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int. J. Clin. Pharmacol. Ther. 48(10), 678–687 (2010).
Medline CASGoogle Scholar
29 Schwartz S, Etropolski M, Shapiro DY et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr. Med. Res. Opin. 27(1), 151–162 (2011).
Medline CASGoogle Scholar
30 Steigerwald I, Muller M, Kujawa J, Balblanc J-C, Calvo-Alen J. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, Phase 3b study (ORIGINAL RESEARCH). J. Pain Res. 5, 121 (2012a).
Medline CASGoogle Scholar
31 Steigerwald I, Müller M, Davies A et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, Phase 3b study. Curr. Med. Res. Opin. 28(6), 911–936 (2012b).
Medline CASGoogle Scholar
32 Van Der Schrier R, Jonkman K, Van Velzen M et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br. J. Anaesth. 119(6), 1169–1177 (2017).
Medline CASGoogle Scholar
33 Wild J, Grond S, Kuperwasser B et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 10(5), 416–427 (2010).
MedlineGoogle Scholar
34 Vachhani A, Barvaliya M, Naik V, Tripathi CB. Cardiovascular abnormalities with single dose of tapentadol. J. Postgrad. Med. 60(2), 189–191 (2014).
Medline CASGoogle Scholar
35 Calvaruso M, Sinagra E, Castellucci M, Spada M, Raimondo D, Rizzo AG. Palexia crystals in gastrointestinal tract, a new entity associated with death following gastrointestinal hemorrhage. 67(5–6), 373–375 (2015).
Google Scholar
36 Walczyk H, Liu CH, Alafris A, Cohen H. Probable tapentadol-associated serotonin syndrome after overdose. Hosp. Pharm. 51(4), 320–327 (2016).
Medline CASGoogle Scholar
37 Franco DM, Ali Z, Levine B, Middleberg RA, Fowler DR. Case report of a fatal intoxication by Nucynta. Am. J. Forensic Med. Pathol. 35(4), 234–236 (2014).
MedlineGoogle Scholar
38 Kemp W, Schlueter S, Smalley E. Death due to apparent intravenous injection of tapentadol. J. Forensic Sci. 58(1), 288–291 (2013).
MedlineGoogle Scholar
39 Cantrell FL, Mallett P, Aldridge L, Verilhac K, Mcintyre IM. A tapentadol related fatality: case report with postmortem concentrations. Forensic Sci. Int. 266, e1–e3 (2016).
Medline CASGoogle Scholar
40 Khaja M, Lominadze G, Millerman K. Cardiac arrest following drug abuse with intravenous tapentadol: case report and literature review. Am. J. Case Rep. 18, 817–821 (2017).
MedlineGoogle Scholar
41 Larson SJ, Pestaner J, Prashar SK, Bayard C, Zarwell LW, Pierre-Louis M. Postmortem distribution of tapentadol and N-desmethyltapentadol. J. Anal. Toxicol. 36(6), 440–443 (2012).
Medline CASGoogle Scholar
42 Tsutaoka BT, Ho RY, Fung SM, Kearney TE. Comparative toxicity of tapentadol and tramadol utilizing data reported to the national poison data system. Ann. Pharmacother. 49(12), 1311–1316 (2015).
Medline CASGoogle Scholar
43 Borys D, Stanton M, Gummin D, Drott T. Tapentadol toxicity in children. Pediatrics 135(2), e392–e396 (2015).
MedlineGoogle Scholar
44 Stollenwerk A, Sohns M, Heisig F, Elling C, Von Zabern D. Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv. Therapy 35(1), 12–30 (2018).
Medline CASGoogle Scholar
45 Tsutaoka B, Ho R, Kearney T. Tapentadol vs tramadol: comparative toxicity utilizing data reported to the national poison data system. Clin. Toxicol. 50(7), 669 (2012).
Google Scholar
46 Steigerwald I, Muller M, Davies A et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr. Med. Res. Opin. 28(6), 911–936 (2012).
Medline CASGoogle Scholar
47 Russo M, Santarelli D, Isbister G. Comment on “probable tapentadol-associated serotonin syndrome after overdose”. Hosp. Pharm. 52(4), 248 (2017).
MedlineGoogle Scholar
48 Mullins ME, Dribben WH. Comment on tapentadol and serotonin syndrome. Hosp. Pharm. 52(4), 246–247 (2017).
MedlineGoogle Scholar
49 Gressler LE, Hammond DA, Painter JT. Serotonin syndrome in tapentadol literature: systematic review of original research. J. Pain Palliat. Care Pharmacother. 31, 228–236 (2017).
MedlineGoogle Scholar
50 Tayal G, Grewal A, Mittal R, Bhatia N. “Tapentadol” - a novel analgesic. J. Anaesthesiol. Clin. Pharmacol. 25(4), 463–466 (2009).
Google Scholar
51 Guay DR. Is tapentadol an advance on tramadol? Consult. Pharm. 24(11), 833–840 (2009).
MedlineGoogle Scholar
52 Chen A, Ashburn MA. Cardiac effects of opioid therapy. Pain Med. (United States) 16, S27–S31 (2015).
MedlineGoogle Scholar
53 Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Safety 1–9 (2018).
MedlineGoogle Scholar
54 Raffa RB. On subclasses of opioid analgesics. Curr. Med. Res. Opin. 30(12), 2579–2584 (2014).
Medline CASGoogle Scholar
55 Christoph A, Eerdekens M-H, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain 158(9), 1813–1824 (2017).
Medline CASGoogle Scholar
56 Häuser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2(3), e599 (2017).
MedlineGoogle Scholar
57 Vosburg SK, Severtson SG, Dart RC et al. Assessment of tapentadol API abuse liability with the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) system. J. Pain 19(4), 439–453 (2017).
MedlineGoogle Scholar

Vol. 8, No. 5

Metrics

Downloaded 476 times

History

Received 7 May 2018

Accepted 22 June 2018

Published online 6 August 2018

Published in print September 2018

Information

Keywords

Financial & competing interests disclosure

SA Schug is/was a member of the international and the Australian Advisory Board for tapentadol. His employer UWA, but not he personally, has received consulting fees, speaking honoraria and travel grants from the manufacturers of tapentadol, Grunenthal, bioCSL and Seqirus, in the last 5 years. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Systematic review registration number: PROSPERO registration number CRD42017074320

PDF download

Toxicity of tapentadol: a systematic review

Abstract

References